Skip to content

Released Mar 27, 2025, before the open

10-K filed Mar 27, 2025, 86 days after period end · 0002023658-25-000012

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$20.96MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$26,637,000—
Operating Cash Flowderived-$30,032,000N/M
Free Cash Flowderived-$30,072,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figures
Net Income-$20.96M-$12.44M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR